CClinicalTrials.gg
Status unknownNCT03710174Updated Oct 18, 2018

Evaluation of the Effectiveness of Infrared LED Photobiomodulation in Children With Sleep Bruxism

A Phase 2 interventional study of Infrared LED photobiomodulation and Occlusal splint in Bruxism, Sleep, sponsored by University of Nove de Julho. Status unknown at 1 site in Brazil. Open to participants aged 7 Years to 10 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-18.

Sponsored by University of Nove de Julho · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2018), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Aug 2017, registered Oct 2018).
Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
7 Years to 10 Years
Sex
All
01

Study summary

Sleep bruxism is a masticatory muscle activity characterized as rhythmic (phasic) or non-rhythmic (tonic). The literature reports the prevalence rates, diverse etiologies and different types of treatment. In children and adolescents, etiological factors, such as breathing pattern and sleep quality, have recently been addressed in studies investigating sleep bruxism. While studies have also reported psychological factors as a causal factor, this aspect requires further research. There are also divergences in opinion regarding the form of treatment. New therapies for adults, such as botulinum toxin, have been investigated, but such techniques are not applicable for individuals in the growth and development phase. Thus, photobiomodulation therapy has piqued the interest of researchers, as this noninvasive method has demonstrated positive results in problems related to muscle tissues. This document describes the protocol for a proposed study to evaluate morphological and psychosocial aspects in children and adolescents with awake bruxism and their responses to photobiomodulation therapy with infrared LED.

02

Conditions studied

  • Bruxism, Sleep
03

In context

Bruxism

166 studies on the registry are indexed under Bruxism; 38 are open to participants now.

This study's planned enrollment of 20 is below the median of 38 across 103 interventional studies indexed under Bruxism.

Browse Bruxism studies →

Lead sponsor

University of Nove de Julho is the lead sponsor of 239 studies on the registry; 51 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 1 (13%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
7 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • mixed dentition phase (permanent incisors and molars erupted)
  • established permanent dentition.

Exclusion criteria

Exclusion Criteria:

  • dental caries
  • using medications, such as anti-inflammatory agents, muscle relaxants, corticoids, anticonvulsants and antidepressants
  • those with chronic diseases that affect muscles or motor coordination
  • those who do not cooperate during the evaluation
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • No intervention
    Control group

    Without bruxism and no intervention. They will be submitted to electromyographic assessment and evaluation of salivary cortisol and dopamine.

  • Experimental
    LED group

    The volunteers in Group 2 will be submitted to the initial evaluation of the morphological and psychosocial variables. During the same appointment, red LED (3 X 6 cm) will be administered using a board with 6 LEDs with a wavelength of 650 nm ± 20 nm, seven-minute operation time, optical spot of 5 ± 2 mm and optical output of 2\~5 mW, with a dose of 2.675 J/cm2. Further analyses will be performed immediately after the photobiomodulation session and one week later. They will be submitted before and after LED to electromyographic assessment and evaluation of salivary cortisol and dopamine.

    Radiation: Infrared LED photobiomodulation

  • Experimental
    Occlusal splint group

    They will be treated using the standard protocol of a rigid occlusal splint. After the initial evaluation, molds will be made for the fabrication of the splints, which will be delivered one week later. Written and verbal instructions for use will be given. After one month of daily use, the volunteers will return for the final morphological and psychosocial evaluations.

    Device: Occlusal splint

  • Placebo comparator
    Placebo group

    Subjects with bruxism. The same procedures as LED group, but the device will be turn off.

    Radiation: Placebo LED photobiomodulation

Interventions

  • RadiationInfrared LED photobiomodulation

    Infrared LED (3 X 6 cm) will be administered using a board with 6 LEDs with a wavelength of wavelength: 850 nm ± 20 nm, seven-minute operation time, optical spot of 5 ± 2 mm and optical output of 2\~5 mW, with a dose of 2.675 J/cm2. Further analyses will be performed immediately after the photobiomodulation session and one week later.

  • DeviceOcclusal splint

    After the initial evaluation, molds will be made for the fabrication of the splints, which will be delivered one week later. Written and verbal instructions for use will be given. After one month of daily use, the volunteers will return for the final morphological and psychosocial evaluations.

  • RadiationPlacebo LED photobiomodulation

    The same procedure as LED group with the device turned off.

06

What researchers measure

Primary outcomes

  1. Change in muscle activity evaluated by electromyography

    Electromyography will be performed to complement the evaluation of the morphological aspects of the groups. The masseter and temporal muscles will be evaluated using a portable electromyograph (BTS TMJOINT) with wireless electrodes. The participant will be seated with Camper's plane parallel to the floor. Three readings will be made on both sides with the muscles at rest, during habitual maximum intercuspation (isometric contraction) and during simulated chewing with Parafilm (isotonic contraction). The signal will be captured for 10 seconds under each condition. The first chewing cycle will be discarded and the subsequent five cycles will be collected.

    Time frame: Before and immediately after treatment

Secondary outcomes

  1. Change in salivary cortisol and dopamine

    The participants and caregivers will receive verbal and written instructions to avoid any physical activity, the ingestion of substances with alcohol or caffeine, soft drinks, tea, corticoids and chewing gum in the 24h prior to the collection of the saliva. Saliva samples will be collected using swabs, which will refrigerated immediately after collection. The swab will be placed under the tongue. Samples with visible signs of blood will be discarded due to possible contamination. The swabs will be centrifuged at 3500 rpm for 5 minutes. The supernatant will be collected and stored at -40o C. Cortisol will be determined using an enzyme-linked immunosorbent assay. Dopamine will also be determined using an ELIZA kit. The samples will be thawed and centrifuged again. The procedure will follow the basic ELISA principle of competition between an untagged antigen and an enzyme-tagged antigen for a particular number of binding sites on the antibody.

    Time frame: Before and immediately after treatment

07

Study locations

1 of 1 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 18, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03710174
Lead sponsor
University of Nove de Julho
Responsible party
Fernanda Yukie Kobayashi (Principal investigator, University of Nove de Julho) — Principal investigator
First posted
Oct 18, 2018
Start date
Aug 1, 2017
Primary completion
Aug 1, 2018
Completion
Apr 10, 2019 (estimated)
Last update
Oct 18, 2018

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion